Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Addex Therapeutics Ltd. (ADXN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Announces Plan to Implement ADS Ratio Change Ad Hoc Announcement Pursuant to Art. 53 LR"
08/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
":",
":",
":"
08/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration Discovery collaboration on track to deliver clinical candidates for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR"
07/24/2023 6-K Quarterly results
06/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Shareholders Approve All Resolutions at Annual General Meeting"
05/18/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency"
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
":",
":",
":"
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Cohort 1 progressing through Part 2 Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the ADX71149 Phase 2 epilepsy clinical study has been recommended to continue by an Independent Interim Review Committee following review of unblinded data from Part 1 of patient Cohort 1. The clinical study is being conducted by Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. “The recommendation of the IRC and the decision of o..."
05/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Convenes Annual General Meeting 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual General Meeting will take place on Wednesday May 31, 2023, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva . Agenda"
04/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Form of Warrant",
"Form of Pre-Funded Warrant",
"Form of Amended and Restated 2021 Warrant",
"Form of Amended and Restated 2022 Warrant",
"Opinion of Homburger AG",
"Securities Purchase Agreement, by and between the Company and the Purchaser",
"Letter Agreement, by and between the Company and the Purchaser"
04/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 4, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that dipraglurant could have beneficial effects on non-motor symptoms experienced by Parkinson’s patients in addition to its established positive effects on dyskinesias. Dipraglurant is an mGlu5 negative allosteric modulator that has successfully completed a Phase 2a study in Parkinson’s disease patients suffering from levodopa induced dyskinesia . “For some time, we have known that excessive glutamate activity from degeneration of the nigro..."
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Raises $5.0 Million in Equity Financing"
03/30/2023 6-K Quarterly results
02/09/2023 6-K Quarterly results
02/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 6, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that enrollment into Part 1 of the Phase 2 clinical study of ADX71149 for the treatment of epilepsy has been completed. ADX71149 is a selective metabotropic glutamate type 2 receptor positive allosteric modulator . The trial is being conducted by Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Data from Part 1 will now be evaluated by an independent interim review committee to ensure the study remains blinded. Based on the outco..."
01/19/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Provides Corporate Update and Financial Guidance Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guidance. “We ended 2022 with CHF7.0 million of cash and expect to be able to finance our operations until Q3 2023. We continue to focus on entering into collaborative arrangements across our pipeline to secure the financial resources to advance their development and strengthen our balance sheet,” said Tim Dyer, CEO of Addex. “We also look forward to our Partner Janssen completing part 1 of the Phase 2 epilepsy study this quarter and repo..."
12/08/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
11/03/2022 6-K Quarterly results
11/01/2022 6-K Quarterly results
08/18/2022 6-K Quarterly results
08/15/2022 6-K Quarterly results
07/26/2022 6-K Quarterly results
07/22/2022 6-K Quarterly results
07/21/2022 6-K Quarterly results
07/21/2022 6-K Quarterly results
06/17/2022 6-K Quarterly results
05/27/2022 6-K Quarterly results
05/10/2022 6-K Quarterly results
05/05/2022 6-K Quarterly results
04/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study Top-line Data Scheduled to Report in Q2 2022 Ad Hoc Announcement Pursuant to Art. 53 LR"
04/06/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Forward Looking Statements:"
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Addex Forward Looking Statements:"
03/10/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy